Design Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview

Design Therapeutics

04/08/2023 14:38

* Design Therapeutics Inc  DSGN.OQ   DSGN.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Design Therapeutics
Inc
is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $22.5​, above​ its last closing price
of $7.61. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.36       -0.36      -0.35     Beat    2.6
 Dec. 31 2023  -0.38       -0.34      -0.31     Beat    9.9
 Sep. 30 2022  -0.29       -0.29      -0.32     Missed  -11.1​
 Jun. 30 2022  -0.25       -0.25      -0.27     Missed  -8
 ​​Mar.        -0.22       -0.22      -0.24     Missed  -9.1
 31 2022                                                
 Dec. 31 2021  -0.25       -0.23      -0.20     Beat    11.8​
 Sep. 30 2021  -0.14       -0.14      -0.21     Missed  -50
 Jun. 30 2021  -0.18       -0.18      -0.14     Beat    23.6
 This summary was machine generated August 4 at 13:38 GMT.  All
figures in US dollars  unless otherwise stated